Webinar schedule
Register now for our upcoming educational webinar sessions
From Theory to Therapy: A Review of Radioisotope Production with a Focus on Ac-225
Monday, October 20th | 12pm ET
Presented by: Jace Taylor, B.S. Chemistry | Nuclear Manufacturing, Cardinal Health NPHS
Learning objectives
- Compare/contrast current methods of radioisotope production.
- Describe the current state of Ac-225 production and utilization.
- Discuss the regulatory pathway and considerations with radiopharmaceutical production.
The Phoenix Rising: SPECT/CT's Rebirth in the Modern Imaging Landscape
Monday, October 20th | 3pm ET
Presented by: Munir Ghesani MD, FACNM, FACR, FSNMMI | Medical Director and Chief Medical Officer, United Theranostics
Learning objectives
- Explain the fundamental technological advancements in SPECT/CT hardware and software that have enabled its resurgence in the modern imaging landscape.
- Discuss how the enhanced quantitative capabilities of contemporary SPECT/CT systems, including accurate absolute activity quantification, are driving their expanding role in theranostics and personalized radiopharmaceutical therapy dosimetry.
- Analyze the current clinical impact and future potential of SPECT/CT in diverse applications beyond traditional uses, including advanced diagnostic studies and its pivotal role in patient stratification and treatment monitoring for novel radiopharmaceuticals.
- Identify the remaining challenges for SPECT/CT, such as standardization and resolution limitations, and consider how ongoing innovations, particularly in artificial intelligence, aim to enhance its performance and broader clinical adoption further.
ClinicalTrials.gov Dissected – 2025 Progress in Nuclear Medicine Clinical Trials
Tuesday, October 21st | 12pm ET
Presented by: Becca Segrest, PharmD I Area Pharmacy Manager, Oklahoma and SW Missouri I Cardinal Health NPHS
Learning objectives
- Review the basics of drug development leading to FDA approval
- Examine current nuclear medicine clinical trial statistics by multiple segmentations
- Analyze progress of theranostic clinical trials from prior year
Empowering Technologists in Theranostics: Advancing Training, Safety, and Collaboration for Radiopharmaceutical Therapies
Medical Society Spotlight Session - Presented by SNMMI-TS
Tuesday, October 21st | 3pm ET
Presented by:
- Megan Hungerford CNMT, (NMTCB)(CT) | Nuclear Medicine and PET/CT Manager, Hartford Hospital
- David Gilmore, EdD, CNMT, NCT, RT(R)(N), FSNMMI-TS | Program Director & Associate Professor, Nuclear Medicine Technology, Massachusetts College of Pharmacy and Health Sciences
Learning objectives
- Highlight the evolving role of technologists in the delivery of radiopharmaceutical therapies within theranostics programs.
- Identify training and education needs for technologists to ensure safe, effective, and standardized therapy delivery.
- Discuss current barriers and solutions related to infrastructure, workforce development, and regulatory requirements impacting technologists.
- Explore interdisciplinary collaboration to optimize patient care and expand access to theranostics services.
- Promote strategies for advancing technologist-led initiatives in clinical practice, research, and program development in theranostics.
Vizamyl™ (flutemetamol F 18 injection) in Clinical Practice: From Imaging to Impact in Alzheimer’s Diagnostics1
Presented by GE HealthCare
Wednesday, October 22nd | 12pm ET
Presented by: Jodi Hawkins, CNMT | Clinical Applications Specialist
Learning objectives
- Amyloid pathology and progression in Alzheimer's disease
- Appropriate use criteria for amyloid PET and Vizamyl's™ expanded label
- Using Vizamyl™: Key steps in Vizamyl™ patient prep, injection, proper orientation, image acquisition, and processing
- Quantification as a valuable additional tool in amyloid PET imaging with Vizamyl™
- Evolving role of amyloid imaging in the context of emerging Alzheimer’s therapies
Advancing Cardiac PET MPI with Flyrcado™ (Flurpiridaz F 18) injection: Considerations for Clinical Practice2
Presented by GE HealthCare
Wednesday, October 22nd | 3pm ET
Presented by: April Mann, MBA, CNMT, NCT, RT(N) | Cardiology KOL and Stakeholder Engagement Lead – PDx
Learning objectives
- Discuss the imaging characteristics and benefits of Flyrcado™
- Discuss patient preparation for Flyrcado™
- Discuss Flyrcado™ imaging protocols
- Discuss processing and display considerations
- Understand the technologist’s role in optimizing image acquisition, reducing artifacts, and ensuring accurate patient positioning for high-quality diagnostic outcomes
- Identify standards uptake patterns with various disease presentation
Management Insights on Launching Radiopharmaceutical Therapy Programs: Is it a Wise Investment?
Thursday, October 23rd | 3pm ET
Presented by:
- Megan Hungerford CNMT, (NMTCB)(CT) I Nuclear Medicine and PET/CT Manager, Hartford Hospital
- Christopher Smitherman, MS, DABR, DABSNM I Chief Diagnostic Medical Physicist, Radiation Safety Officer, Hartford HealthCare
Learning objectives
- Identify initial requirements for launching a radiopharmaceutical therapy program
- Explain the various methods for administering therapeutic radiopharmaceuticals
- Describe clinical practices and documentation requirements associated with radiopharmaceutical therapies
Diving Deeper into 68Ga-PSMA-11
Encore Session sponsored by Telix Pharmaceuticals Limited
Wednesday, November 5th | 3pm ET
Presented by: Kim Ramos, BS, CNMT, ARRT(CT)
Learning objectives
- Examine chemical structure, mechanism of action, and production of 68Ga-PSMA-11
- Discuss patient procedure and clinical workflow
- Review 68Ga-PSMA-11 utility in staging, recurrence, and therapy planning
Form title
Cardinal Health Center for Theranostics Advancement
Watch the video to learn more about how Cardinal Health's Center for Theranostics Advancement is supporting the growth of theranostics globally:
Learn more about nuclear theranostics at cardinalhealth.com/theranostics
Theranostics Week webinars are for educational purposes only and not intended as legal, compliance, medical or business advice. Cardinal Health disclaims any and all warranties expressed or implied regarding the information provided as part of these webinars or any other webinar offered by Cardinal Health. Each webinar participant remains solely responsible for all compliance and legal requirements applicable to such participant’s own activities. Health care providers are responsible for all medical decisions regarding the use of any drug products with their patients.
**Cardinal Health provided Continuing Education (CE) courses are pending approval by the Society of Nuclear Medicine and Molecular Imaging-Technologists Section VOICE – Category A. Valid for both ARRT and NMTCB CE requirements for renewal of registration certificates.
1Product Indications and Important Safety Information – VIZAMYL™ (flutemetamol F 18 injection) is indicated for positron-emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for:
- Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline
- Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing of information of the therapeutic products.
A negative scan indicates sparse to no neuritic plaques. In patients being evaluated for AD and other causes of cognitive decline who have not been treated with amyloid beta-directed therapy, a negative scan is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition and reduces the likelihood that a patient’s cognitive impairment is due to AD. A negative scan result does not preclude the accumulation of amyloid beta in the brain in the future.
A positive scan establishes the presence of moderate to frequent neuritic plaques. Neuropathological examination has shown that moderate to frequent amyloid beta neuritic plaques are present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Full prescribing information can be found here: gehealthcare.com/vizamyl-pi.
2FLYRCADO™ (flurpiridaz F 18) injection, for intravenous use important safety information IMPORTANT SAFETY INFORMATION Indications and Usage FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction. Full prescribing information can be found here: flyrcado-pi.pdf.
© 2025 Cardinal Health. All Rights Reserved. CARDINAL HEALTH, the CARDINAL HEALTH LOGO, and ESSENTIAL TO CARE are trademarks of Cardinal Health and may be registered in the US and/or in other countries. Patent cardinalhealth.com/patents.